Pharnext S.a.s

Pharnext S.a.s is a company in Paris, France that has taken part in 2 EU-funded projects since 2008, receiving €540k in EU funding.

EU funding received€540k
EU projects2
As coordinator0
Running now0
First EU project2008
Latest project2008
CountryFrance
EU registration (PIC)999729822
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Pharnext S.a.s's own share of each project, not the project's full budget.

  • FP7 (2007 to 2013)€540k · 2 projects

Projects

2 EU-funded projects, newest first. Each links to the official record.

  • HYPERGENESPartner

    European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model

    FP7 (2007 to 2013) · 2008–2011 · Project on CORDIS ↗

    €306ktheir share
  • POCEMONPartner

    Point-Of-Care MONitoring and DIagnostics for Autoimmune Diseases

    FP7 (2007 to 2013) · 2008–2011 · Project on CORDIS ↗

    €234ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • autoimmune diseases
  • epidemiology
  • genomes
  • lab on a chip
  • machine learning
  • multiple sclerosis
  • rheumatology
  • software development

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime